logo
0

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Comparative Efficacy Of Ldlclowering Therapies In Firsttime Vs Recurrent Myocardial Infarction Prevention A Metaanalysis Of Largescale Randomized Controlled Trials Baoqiang Guo

  • SKU: BELL-239008364
Comparative Efficacy Of Ldlclowering Therapies In Firsttime Vs Recurrent Myocardial Infarction Prevention A Metaanalysis Of Largescale Randomized Controlled Trials Baoqiang Guo
$ 35.00 $ 45.00 (-22%)

4.0

86 reviews

Comparative Efficacy Of Ldlclowering Therapies In Firsttime Vs Recurrent Myocardial Infarction Prevention A Metaanalysis Of Largescale Randomized Controlled Trials Baoqiang Guo instant download after payment.

Publisher: x
File Extension: PDF
File size: 1.4 MB
Pages: 12
Author: Bao-Qiang Guo, Hong-Bin Li, Bing Zhao, Peng-Wei Xu
ISBN: 10.1093/EURJPC/ZWAF336
Language: English
Year: 2025

Product desciption

Comparative Efficacy Of Ldlclowering Therapies In Firsttime Vs Recurrent Myocardial Infarction Prevention A Metaanalysis Of Largescale Randomized Controlled Trials Baoqiang Guo by Bao-qiang Guo, Hong-bin Li, Bing Zhao, Peng-wei Xu 10.1093/EURJPC/ZWAF336 instant download after payment.

Reducing elevated low-density lipoprotein cholesterol (LDL-C) is central to global efforts to prevent myocardial infarction (MI). While many studies have evaluated LDL-C-lowering therapies in first-time and recurrent MI prevention, direct comparisons of their relative efficacy are lacking. Therefore, we conducted a systematic review and meta-analysis to compare the efficacy of LDL-C-lowering therapies in first-time vs. recurrent MI prevention. 
-
Methods and results: We searched three databases until 30 November 2024, for randomized controlled trials (RCTs) with at least 1000 patient-years of follow-up. Efficacy was quantified as relative risk (RR) with 95% confidence intervals (CIs). Differences in benefit magnitude were assessed using Cochran’s Q test. Data were pooled with a random-effects model, and heterogeneity was measured using the I2 statistic.